[1]
Mody BP, Khan MH, Zaid S, Ahn C, Lloji A, Aronow WS, Gupta CA, Levine A, Gass AL, Cooper HA, Lanier GM. Survival With Continuous Outpatient Intravenous Inotrope Therapy in the Modern Era. American journal of therapeutics. 2020 Oct 1:28(6):e621-e630. doi: 10.1097/MJT.0000000000001260. Epub 2020 Oct 1
[PubMed PMID: 33021537]
[2]
Tariq S, Aronow WS. Use of Inotropic Agents in Treatment of Systolic Heart Failure. International journal of molecular sciences. 2015 Dec 4:16(12):29060-8. doi: 10.3390/ijms161226147. Epub 2015 Dec 4
[PubMed PMID: 26690127]
[3]
McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. Journal of critical care. 2006 Jun:21(2):217-22
[PubMed PMID: 16769471]
[4]
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. The New England journal of medicine. 1991 Nov 21:325(21):1468-75
[PubMed PMID: 1944425]
[5]
Curley M, Liebers J, Maynard R. Continuous Intravenous Milrinone Therapy in Pediatric Outpatients. Journal of infusion nursing : the official publication of the Infusion Nurses Society. 2017 Mar/Apr:40(2):92-96. doi: 10.1097/NAN.0000000000000214. Epub
[PubMed PMID: 28248808]
[6]
Imam SS, El-Farrash RA, Taha AS, Saleh GA. Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial. Journal of cardiovascular pharmacology. 2022 Nov 1:80(5):746-752. doi: 10.1097/FJC.0000000000001332. Epub 2022 Nov 1
[PubMed PMID: 35881893]
Level 1 (high-level) evidence
[7]
Qasim A, Jain SK. Milrinone Use in Persistent Pulmonary Hypertension of the Newborn. NeoReviews. 2020 Mar:21(3):e165-e178. doi: 10.1542/neo.21-3-e165. Epub
[PubMed PMID: 32123121]
[8]
Dobashi S, Watanabe I, Nakanishi R, Hisatake S, Kiuchi S, Kabuki T, Oka T, Fujii T, Ikeda T. Comparing the effects of milrinone and olprinone in patients with congestive heart failure. Heart and vessels. 2020 Jun:35(6):776-785. doi: 10.1007/s00380-019-01543-6. Epub 2019 Dec 21
[PubMed PMID: 31865433]
[9]
Fredholm M, Jörgensen K, Houltz E, Ricksten SE. Inotropic and lusitropic effects of levosimendan and milrinone assessed by strain echocardiography-A randomised trial. Acta anaesthesiologica Scandinavica. 2018 Oct:62(9):1246-1254. doi: 10.1111/aas.13170. Epub 2018 Jun 21
[PubMed PMID: 29926912]
Level 1 (high-level) evidence
[10]
Ginwalla M, Tofovic DS. Current Status of Inotropes in Heart Failure. Heart failure clinics. 2018 Oct:14(4):601-616. doi: 10.1016/j.hfc.2018.06.010. Epub 2018 Aug 17
[PubMed PMID: 30266368]
[11]
Wang H, Gong M, Zhou B, Dai A. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Advances in therapy. 2009 Apr:26(4):462-8. doi: 10.1007/s12325-009-0019-4. Epub 2009 Apr 16
[PubMed PMID: 19381522]
Level 3 (low-level) evidence
[12]
Holmes CL, Walley KR. Vasoactive drugs for vasodilatory shock in ICU. Current opinion in critical care. 2009 Oct:15(5):398-402. doi: 10.1097/MCC.0b013e32832e96ef. Epub
[PubMed PMID: 19542884]
Level 3 (low-level) evidence
[13]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3:145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1
[PubMed PMID: 35363499]
Level 1 (high-level) evidence
[14]
Chong LYZ, Satya K, Kim B, Berkowitz R. Milrinone Dosing and a Culture of Caution in Clinical Practice. Cardiology in review. 2018 Jan/Feb:26(1):35-42. doi: 10.1097/CRD.0000000000000165. Epub
[PubMed PMID: 29045285]
[15]
Samiee-Zafarghandy S, Raman SR, van den Anker JN, McHutchison K, Hornik CP, Clark RH, Brian Smith P, Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee. Safety of milrinone use in neonatal intensive care units. Early human development. 2015 Jan:91(1):31-5. doi: 10.1016/j.earlhumdev.2014.10.007. Epub 2014 Nov 26
[PubMed PMID: 25460254]
[16]
Nguyen AQ, Denault AY, Théoret Y, Perrault LP, Varin F. Inhaled milrinone in cardiac surgical patients: a pilot randomized controlled trial of jet vs. mesh nebulization. Scientific reports. 2020 Feb 7:10(1):2069. doi: 10.1038/s41598-020-58902-x. Epub 2020 Feb 7
[PubMed PMID: 32034202]
Level 3 (low-level) evidence
[17]
Charisopoulou D, Leaver N, Banner NR. Milrinone in advanced heart failure: dose and therapeutic monitor outside intensive care unit. Angiology. 2014 Apr:65(4):343-9. doi: 10.1177/0003319713485808. Epub 2013 Apr 25
[PubMed PMID: 23620310]
[18]
Rodriguez-Ziccardi M, Rubio M, Lu M, Greenspan A. Ventricular tachyarrhythmia in a 78-year-old woman with essential thrombocythaemia. BMJ case reports. 2018 Feb 8:2018():. pii: bcr-2017-220723. doi: 10.1136/bcr-2017-220723. Epub 2018 Feb 8
[PubMed PMID: 29437800]
Level 3 (low-level) evidence
[19]
Faraday N. Perioperative platelet activation and the inhibitory effect of milrinone. Anesthesiology. 2009 Dec:111(6):1185-6. doi: 10.1097/ALN.0b013e3181c155ee. Epub
[PubMed PMID: 19934858]
[20]
Mladěnka P, Applová L, Patočka J, Costa VM, Remiao F, Pourová J, Mladěnka A, Karlíčková J, Jahodář L, Vopršalová M, Varner KJ, Štěrba M, TOX-OER and CARDIOTOX Hradec Králové Researchers and Collaborators. Comprehensive review of cardiovascular toxicity of drugs and related agents. Medicinal research reviews. 2018 Jul:38(4):1332-1403. doi: 10.1002/med.21476. Epub 2018 Jan 5
[PubMed PMID: 29315692]
[21]
Gist KM, Goldstein SL, Joy MS, Vinks AA. Milrinone Dosing Issues in Critically Ill Children With Kidney Injury: A Review. Journal of cardiovascular pharmacology. 2016 Feb:67(2):175-81. doi: 10.1097/FJC.0000000000000327. Epub
[PubMed PMID: 26448275]
[22]
Nieminen MS, Dickstein K, Fonseca C, Serrano JM, Parissis J, Fedele F, Wikström G, Agostoni P, Atar S, Baholli L, Brito D, Colet JC, Édes I, Gómez Mesa JE, Gorjup V, Garza EH, González Juanatey JR, Karanovic N, Karavidas A, Katsytadze I, Kivikko M, Matskeplishvili S, Merkely B, Morandi F, Novoa A, Oliva F, Ostadal P, Pereira-Barretto A, Pollesello P, Rudiger A, Schwinger RH, Wieser M, Yavelov I, Zymliński R. The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International journal of cardiology. 2015 Jul 15:191():256-64. doi: 10.1016/j.ijcard.2015.04.235. Epub 2015 May 1
[PubMed PMID: 25981363]
Level 2 (mid-level) evidence
[23]
Burniston JG, Ellison GM, Clark WA, Goldspink DF, Tan LB. Relative toxicity of cardiotonic agents: some induce more cardiac and skeletal myocyte apoptosis and necrosis in vivo than others. Cardiovascular toxicology. 2005 Fall:5(4):355-64
[PubMed PMID: 16382173]
[24]
Zierler BK, Abu-Rish Blakeney E, O'Brien KD, Teams IHF. An interprofessional collaborative practice approach to transform heart failure care: An overview. Journal of interprofessional care. 2018 May:32(3):378-381. doi: 10.1080/13561820.2018.1426560. Epub 2018 Jan 17
[PubMed PMID: 29338459]
Level 3 (low-level) evidence